WINTON GROUP Ltd boosted its position in ChemoCentryx, Inc. (NASDAQ:CCXI) by 123.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 35,493 shares of the biopharmaceutical company’s stock after acquiring an additional 19,589 shares during the quarter. WINTON GROUP Ltd owned 0.05% of ChemoCentryx worth $475,000 at the end of the most recent quarter.
A number of other large investors have also recently modified their holdings of the stock. Alliancebernstein L.P. grew its position in shares of ChemoCentryx by 0.6% during the first quarter. Alliancebernstein L.P. now owns 97,341 shares of the biopharmaceutical company’s stock worth $4,988,000 after acquiring an additional 600 shares during the last quarter. Teacher Retirement System of Texas grew its position in shares of ChemoCentryx by 22.5% during the first quarter. Teacher Retirement System of Texas now owns 5,379 shares of the biopharmaceutical company’s stock worth $276,000 after acquiring an additional 989 shares during the last quarter. UBS Asset Management Americas Inc. grew its position in shares of ChemoCentryx by 1.9% during the first quarter. UBS Asset Management Americas Inc. now owns 59,340 shares of the biopharmaceutical company’s stock worth $3,041,000 after acquiring an additional 1,094 shares during the last quarter. Nisa Investment Advisors LLC lifted its holdings in shares of ChemoCentryx by 56.3% during the second quarter. Nisa Investment Advisors LLC now owns 3,330 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 1,200 shares during the period. Finally, Alps Advisors Inc. lifted its holdings in shares of ChemoCentryx by 1.1% during the first quarter. Alps Advisors Inc. now owns 125,942 shares of the biopharmaceutical company’s stock worth $6,453,000 after purchasing an additional 1,419 shares during the period. 63.20% of the stock is currently owned by hedge funds and other institutional investors.
CCXI has been the subject of several recent research reports. Canaccord Genuity decreased their price target on ChemoCentryx from $79.00 to $64.00 and set a “buy” rating for the company in a report on Wednesday, August 11th. Stifel Nicolaus raised ChemoCentryx from a “hold” rating to a “buy” rating and raised their target price for the company from $26.00 to $31.00 in a report on Tuesday, July 6th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $37.88.
ChemoCentryx (NASDAQ:CCXI) last announced its earnings results on Sunday, August 8th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.55) by ($0.01). ChemoCentryx had a negative net margin of 568.54% and a negative return on equity of 33.17%. The business had revenue of $1.81 million during the quarter, compared to analyst estimates of $4.85 million. During the same period in the previous year, the company earned $0.29 earnings per share. The business’s revenue for the quarter was down 96.3% on a year-over-year basis. On average, analysts forecast that ChemoCentryx, Inc. will post -1.88 earnings per share for the current fiscal year.
ChemoCentryx, Inc is a biopharmaceutical company engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact.
Further Reading: Cash Asset Ratio
Want to see what other hedge funds are holding CCXI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ChemoCentryx, Inc. (NASDAQ:CCXI).
Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.